Hengrui Medicine (600276.SH): Multiple drugs included in the national medical insurance catalog

Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) issued an announcement that some of the company's products have been included in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog" (referred to as the "National Medical Insurance Catalog"). Through medical insurance negotiations, Zemituosita Tablets, Luzunolei Sodium Tablets, and Henggliflozin Retagliptin Metformin Sustained-release Tablets (II) were included in the National Medical Insurance Catalog for the first time; the new indication of Rui Kang Qu Tuo Zhu Monoclonal Antibody for Injection was successfully included in the National Medical Insurance Catalog; Hydroxyethanesulfonate Dalpiciclib Tablets were successfully renewed and a new indication was included in the National Medical Insurance Catalog; Proline Henggliflozin Tablets, Ruiveilutamide Tablets, Tegilidine Fumarate Injection, Oteseconazole Capsules, Henggliflozin Metformin Sustained-release Tablets (I)/(II), Camrelizumab for Injection, and Pregabalin Sustained-release Tablets were successfully renewed and retained in the National Medical Insurance Catalog.